Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s stock price traded down 4.1% during mid-day trading on Thursday . The stock traded as low as $9.23 and last traded at $9.38. 328,591 shares changed hands during trading, a decline of 78% from the average session volume of 1,464,205 shares. The stock had previously closed at $9.78.
Ginkgo Bioworks Price Performance
The firm has a market cap of $547.22 million, a P/E ratio of -0.70 and a beta of 1.25. The company has a fifty day moving average of $7.54 and a 200-day moving average of $9.07.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. The firm had revenue of $48.32 million during the quarter, compared to the consensus estimate of $38.70 million. On average, sell-side analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.
Institutional Trading of Ginkgo Bioworks
A number of hedge funds have recently bought and sold shares of DNA. Bank of America Corp DE raised its stake in shares of Ginkgo Bioworks by 780.6% during the 4th quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock worth $36,967,000 after purchasing an additional 3,336,964 shares during the period. Erste Asset Management GmbH lifted its position in shares of Ginkgo Bioworks by 123.2% during the 1st quarter. Erste Asset Management GmbH now owns 1,650,000 shares of the company's stock valued at $9,405,000 after buying an additional 910,668 shares during the last quarter. Millennium Management LLC grew its stake in shares of Ginkgo Bioworks by 113.1% during the 1st quarter. Millennium Management LLC now owns 1,427,600 shares of the company's stock worth $8,137,000 after acquiring an additional 757,535 shares during the period. Forbes J M & Co. LLP increased its holdings in Ginkgo Bioworks by 56.0% in the 1st quarter. Forbes J M & Co. LLP now owns 1,094,564 shares of the company's stock worth $6,239,000 after acquiring an additional 392,832 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Ginkgo Bioworks by 25.4% in the first quarter. Goldman Sachs Group Inc. now owns 686,767 shares of the company's stock worth $3,915,000 after purchasing an additional 139,126 shares in the last quarter. 78.63% of the stock is currently owned by institutional investors.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
